Actively Recruiting
Glofitamab in Chinese Patients With R/R DLBCL
Led by Peking Union Medical College Hospital · Updated on 2026-03-27
20
Participants Needed
1
Research Sites
260 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study will evaluate the safety and efficacy of glofitamab as a single agent in Chinese patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have failed two or more lines of systemic therapy.
CONDITIONS
Official Title
Glofitamab in Chinese Patients With R/R DLBCL
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically-confirmed diffuse large B-cell lymphoma (DLBCL)
- Relapsed or refractory disease after at least two prior systemic therapies
- Presence of measurable disease
You will not qualify if you...
- Pregnancy or breastfeeding
- Active infection or reactivation of a latent infection
- Active autoimmune disease or immune deficiency
- Severe organ failure: left ventricular ejection fraction below 40%, diffusing capacity of the lungs for carbon monoxide below 40%, estimated glomerular filtration rate below 30 ml/min, or bilirubin level three times above the upper limit of normal
- Dependence on the study sponsor, investigator, or trial site
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China, 100730
Actively Recruiting
Research Team
J
Jing Ruan
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here